Clin2
NCT06323837Possibly a fitRecruiting

Testing mirtazapine for methamphetamine use in people on opioid treatment

Stimulant Use Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests whether the antidepressant mirtazapine can help reduce methamphetamine use in people who are already receiving medication for opioid use disorder. It aims to see if adding this medication improves outcomes for those struggling with both conditions.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You are currently receiving medication for opioid use disorder (like methadone or buprenorphine) at a clinic in Spokane, Washington.
  • You have been diagnosed with methamphetamine use disorder (mild, moderate, or severe).
  • You had at least one positive urine test for methamphetamine at the start of the study or during the first 2 weeks.
  • You are not taking any antidepressant medication (including mirtazapine) in the 30 days before starting.
  • You do not have serious liver or kidney problems, and your vital signs are within normal ranges.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06666010Not yet recruiting· Phase 2
Psilocybin-assisted therapy for stimulant use disorder

This trial tests whether a single dose of psilocybin (PEX010) combined with therapy can help people stop using methamphetamine or other stimulants. It focuses on safety and early signs of effectiveness.

NCT06989853Recruiting· Early Phase 1
Testing troriluzole for methamphetamine use disorder

This study tests whether a medication called troriluzole can help people who use methamphetamine. If you have methamphetamine use disorder and are not seeking treatment right now, this study may be an option for you.

Lexington, Kentucky
NCT07774702Not yet recruiting· Phase 2
Psilocybin for methamphetamine use disorder

This trial tests whether a psychedelic drug called psilocybin can help people cut down or stop using methamphetamine. You'll take the drug in a supervised setting and get support to aim for full abstinence.

Birmingham, Alabama
NCT06207162Recruiting
Brain scans and methadone treatment for opioid recovery

This study uses MRI scans over time to track brain changes in people with opioid use disorder who recently started methadone treatment. You can help researchers understand recovery patterns if you are early in your methadone journey and can commit to repeated visits.

New Haven, Connecticut
NCT07086014Recruiting
Brain response to methamphetamine cues in men

This study uses brain scans to see how men with methamphetamine use disorder react to images or reminders of the drug. It aims to understand cravings and brain activity, which could help improve treatments.

New York, New York
NCT07226596Recruiting
Methamphetamine use: can you reduce without quitting?

This study tests whether people who use methamphetamine can reduce use even if they are not completely abstinent. It offers a 12-week program and checks how you're doing for another 12 weeks after.

Lexington, Kentucky

Hear when a new Stimulant Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.